Open AccessInforming Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis
Author(s) -
The BeAMS Study group,
Natalie Schwehr Mac Arthur,
Karen M. Kuntz,
Eva A. Enns,
Nathan D. Shippee,
Elaine Kingwell,
Helen Tremlett,
Adam F. Carpenter,
Mary Butler
Publication year - 2020
Publication title -
drugs and aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 94
eISSN - 1179-1969
pISSN - 1170-229X
DOI - 10.1007/s40266-019-00741-1
Subject(s) - medicine , discontinuation , natalizumab , fingolimod , multiple sclerosis , pediatrics , expanded disability status scale , quality of life (healthcare) , physical therapy , psychiatry , nursing
For older adults with relapsing-onset multiple sclerosis (MS), limited information is available to inform if, or when, disease-modifying drugs (DMDs) may be safely discontinued.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom